Pharmaceutical

Pharmanovia signs license agreement for Lindis Biotech’s catumaxomab

Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab for malignant ascites.

Nov 21, 2024 - 06:00
Pharmanovia signs license agreement for Lindis Biotech’s catumaxomab
Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab for malignant ascites.
Read the original article

Tags:

Previous Article

Parkinson’s disease cases to reach 3.15 million in 7MM by 2033

Next Article

Wes Streeting says patients should view data sharing ‘the same as taxes’

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Cigna, Humana in talks to merge into health insurance giant, per report

STAT+: Cigna, Humana in talks to merge into health insu...

Nov 29, 2023

STAT+: Covid hospitalizations on the rise, Humana says

STAT+: Covid hospitalizations on the rise, Humana says

Sep 6, 2023

‘Worse than what we thought’: New data reveals deeper problems with the Bureau of Prisons’ Covid response

‘Worse than what we thought’: New data reveals deeper p...

May 23, 2023